Last reviewed · How we verify

Misoprostol (given vaginally)

Hawler Medical University · FDA-approved active Small molecule

Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase uterine contractions and promote cervical ripening and dilation.

Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase uterine contractions and promote cervical ripening and dilation. Used for Cervical ripening and labor induction, Medical abortion (in combination with mifepristone), Prevention of postpartum hemorrhage.

At a glance

Generic nameMisoprostol (given vaginally)
Also known asserial number 022-00, Cytotec, Arthrotec
SponsorHawler Medical University
Drug classProstaglandin analogue
TargetProstaglandin E1 receptor (EP receptor)
ModalitySmall molecule
Therapeutic areaObstetrics/Gynecology
PhaseFDA-approved

Mechanism of action

Misoprostol acts as a synthetic prostaglandin that stimulates uterine smooth muscle contraction and softens the cervix by increasing local prostaglandin receptor signaling. When administered vaginally, it achieves high local concentrations that promote labor induction and cervical preparation. This mechanism makes it effective for medical abortion and labor induction in obstetric settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: